ES2121084T3 - Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos. - Google Patents

Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.

Info

Publication number
ES2121084T3
ES2121084T3 ES93909249T ES93909249T ES2121084T3 ES 2121084 T3 ES2121084 T3 ES 2121084T3 ES 93909249 T ES93909249 T ES 93909249T ES 93909249 T ES93909249 T ES 93909249T ES 2121084 T3 ES2121084 T3 ES 2121084T3
Authority
ES
Spain
Prior art keywords
patient
hydrogen
antihistaminics
hepatic disorders
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909249T
Other languages
English (en)
Inventor
James K Woodward
Richard R Okerholm
Mark G Eller
Bruce E Mcnutt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2121084(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2121084T3 publication Critical patent/ES2121084T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA PROPORCIONAR UN EFECTO ANTIHISTAMINICO EN UN PACIENTE DAÑADO HEPATICAMENTE QUE LO NECESITE, Y QUE CONSISTE EN ADMINISTRAR A DICHO PACIENTE UNA CANTIDAD ANTIHISTAMINICA EFECTIVA DE UN COMPUESTO DE LA FORMULA (I) EN LA QUE R1 ES HIDROGENO O HIDROXI; R2 ES HIDROGENO; O R1 Y R2 JUNTOS FORMAN UN SEGUNDO ENLACE ENTRE LOS ATOMOS DE CARBONO QUE LLEVAN R1 Y R2; N ES UN ENTRE DE 1 A 5; R3 ES -COOH O -COOALKILO EN DONDE LA UNIDAD DE ALKILO TIENE DE 1 A 6 ATOMOS DE CARBONO Y ES DE CADENA RECTA O RAMIFICADA; CADA A Y B ES HIDROGENO O HIDROXI SIEMPRE Y CUANDO AL MENOS UNO DE ENTRE A Y B SEA HIDROGENO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE E ISOMEROS INDIVIDUALES DEL MISMO.
ES93909249T 1992-05-11 1993-04-06 Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos. Expired - Lifetime ES2121084T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88080192A 1992-05-11 1992-05-11
US92289092A 1992-07-31 1992-07-31

Publications (1)

Publication Number Publication Date
ES2121084T3 true ES2121084T3 (es) 2002-02-16

Family

ID=27128589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909249T Expired - Lifetime ES2121084T3 (es) 1992-05-11 1993-04-06 Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.

Country Status (16)

Country Link
US (7) US6037353A (es)
EP (1) EP0639976B1 (es)
JP (1) JPH07506828A (es)
KR (1) KR950701525A (es)
AT (1) ATE194913T1 (es)
AU (1) AU679910B2 (es)
CA (1) CA2134211C (es)
CL (1) CL2004000304A1 (es)
DE (1) DE69320952T2 (es)
DK (1) DK0639976T3 (es)
ES (1) ES2121084T3 (es)
HU (1) HU223774B1 (es)
MX (1) MX9302704A (es)
NO (1) NO307688B1 (es)
NZ (1) NZ251834A (es)
WO (1) WO1993023047A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU223774B1 (hu) * 1992-05-11 2005-01-28 Merrell Dow Pharmaceuticals Inc. Terfenadinszármazékok alkalmazása antihisztamin hatású gyógyszerkészítmények előállítására
DE69334008T2 (de) † 1992-08-03 2006-10-19 Sepracor Inc., Marlborough Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen
IT1271417B (it) * 1993-10-15 1997-05-28 Erregierre Ind Chim Composti ad attivita' antiistaminica procedimento per la loro preperazione e composizioni farmaceutiche che li contengono.
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
CA2189007C (en) 1994-05-18 2004-03-02 Daniel R. Henton Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
MX9706449A (es) 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
WO1999009957A1 (en) * 1997-08-26 1999-03-04 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US20020177608A1 (en) * 2001-04-09 2002-11-28 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
DE03757471T1 (de) * 2002-06-10 2005-09-01 Teva Pharmaceutical Industries Ltd. Polymorphe form xvi von fexofenadin-hydrochlorid
EP1393728A1 (en) * 2002-08-30 2004-03-03 Vrije Universiteit Inverse agonists acting at virus-encoded G protein-coupled receptors
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
CA2560882A1 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
KR20110017365A (ko) * 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
HU223774B1 (hu) * 1992-05-11 2005-01-28 Merrell Dow Pharmaceuticals Inc. Terfenadinszármazékok alkalmazása antihisztamin hatású gyógyszerkészítmények előállítására
DE69334008T2 (de) * 1992-08-03 2006-10-19 Sepracor Inc., Marlborough Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen

Also Published As

Publication number Publication date
NZ251834A (en) 1997-07-27
US6037353A (en) 2000-03-14
DE69320952T2 (de) 1999-05-27
MX9302704A (es) 1994-06-30
CL2004000304A1 (es) 2005-05-27
NO944287D0 (no) 1994-11-10
EP0639976B1 (en) 2000-07-26
HUT71402A (en) 1995-11-28
DE69320952D1 (de) 1998-10-15
EP0639976A1 (en) 1995-03-01
US6187791B1 (en) 2001-02-13
NO944287L (no) 1994-11-10
US20100168166A1 (en) 2010-07-01
AU679910B2 (en) 1997-07-17
HU223774B1 (hu) 2005-01-28
NO307688B1 (no) 2000-05-15
US20030130315A1 (en) 2003-07-10
DK0639976T3 (da) 1999-02-15
US20030055083A1 (en) 2003-03-20
ATE194913T1 (de) 2000-08-15
KR950701525A (ko) 1995-04-28
US20060205782A1 (en) 2006-09-14
US6399632B1 (en) 2002-06-04
CA2134211C (en) 1999-06-29
AU3973493A (en) 1993-12-13
CA2134211A1 (en) 1993-11-25
WO1993023047A1 (en) 1993-11-25
JPH07506828A (ja) 1995-07-27

Similar Documents

Publication Publication Date Title
ES2121084T3 (es) Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.
HK1032226A1 (en) Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/eiphenylmethoxy piperidine derivatives.
ES2126068T3 (es) Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene.
ES2091057T3 (es) Composicion medicinal que mejora el metabolismo de los lipidos.
DE69315827D1 (de) Neue acylierte phospholipid-arzneimittel
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE172959T1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
ES2058315T3 (es) Compuestos eficaces contra insuficiencia cerebral.
HN1999000026A (es) Biciclo (2.2.1) heptanos y compuestos relacionados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639976

Country of ref document: ES

FG2A Definitive protection

Ref document number: 639976

Country of ref document: ES